All the following anti-retroviral drugs produce dyslipidemia except –
**Core Concept**
Dyslipidemia is a common side effect of certain anti-retroviral drugs, particularly those that interfere with lipid metabolism. Protease inhibitors (PIs) and some non-nucleoside reverse transcriptase inhibitors (NNRTIs) are known to cause dyslipidemia due to their effects on lipid synthesis and degradation pathways.
**Why the Correct Answer is Right**
Dyslipidemia associated with anti-retroviral therapy is often characterized by increased triglycerides and LDL cholesterol, and decreased HDL cholesterol. This is primarily due to the inhibition of enzymes involved in lipid metabolism, such as HMG-CoA reductase (target of statins) and lipoprotein lipase. Protease inhibitors, like saquinavir and atazanavir, and some NNRTIs, like nevirapine, have been shown to cause dyslipidemia.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because certain protease inhibitors, such as saquinavir and atazanavir, are known to cause dyslipidemia.
**Option B:** This option is incorrect because some non-nucleoside reverse transcriptase inhibitors, like nevirapine, have been associated with dyslipidemia.
**Option C:** This option is incorrect because the correct answer is not listed, but we can infer that this is the correct answer because it is the option that does not produce dyslipidemia.
**Clinical Pearl / High-Yield Fact**
It's essential to monitor lipid profiles regularly in patients on anti-retroviral therapy, especially those on protease inhibitors or NNRTIs, to prevent cardiovascular complications.
**Correct Answer: C.**